Mayne enters US women’s health market with NASDAQ-listed partner for $205m; shareholders spookedIn a deal the company expects to be immediately material to its own revenues and profits, Australia’s Mayne Pharma (ASX:MYX) is entering the US women’s healthcare product market with NASDAQ-listed partner TherapeuticsMD. Executing a licencing agreement with Therapeutics, Mayne will hand the former $205.5m to fund the product-line acquisition.Payments to Therapeutics MD by Mayne will be made on sales-based milestones; for every US$100m in revenue made each year, Mayne will need to hand TherapeuticsMD $5m. Mayne will also pay royalties of US$3m a year for 12 years.
Mayne Pharma has an extensive women’s health portfolio focused on contraceptives.
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.45 |
Change
-0.290(5.05%) |
Mkt cap ! $463.6M | |||
| Open | High | Low | Value | Volume |
| $5.73 | $5.73 | $5.45 | $2.780M | 502.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 906 | $5.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.54 | 1328 | 1 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$5.47 |
Change
-0.290 ( 4.48 %) |
||||
| Open | High | Low | Volume | ||
| $5.65 | $5.67 | $5.45 | 53573 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| MYX (ASX) Chart |